Dublin, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Pain Management- New Discoveries And Treatment Options In Abuse Deterrent Era" report to their offering. In this report, we have discussed a number of novel delivery technologies employed in the formulating abuse deterrent product, technologies employed in enhancing patient compliances, emerging novel mechanisms and late stage pipeline drugs in the management of pain.
Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing Opioids for Chronic Pain (2016) are definite steps taken by FDA in last two years for creating Abuse Deterrent Era in a short span to stop opioid abuse and reversing opioid epidemic in USA. There were around 18,893 deaths involving prescription of opioids in the United States in 2014 which was up 16% from 2013 as per NCHS (National Center for Health Statistics). Around +6 plus extended release abuse deterrent formulations with Abuse deterrent (AD) labels are approved in last two years (Xtampza ER, MorphaBond ER, Hysingla ER, Embeda ER, Targiniq ER, Oxaydo) and are expected to provide improvements over existing formulations for abuse deterrent purpose. But they have some limitation for restricting abuse mainly through oral intake- swallowing a number of intact tablets or capsules. Despite, Extended release (ER) Abuse Deterrent Formulations partly control Opioids abuse (through nasal or injection routes), ER opioids has high potential of abuse, its AD formulation add significant value to create Abuse Deterrent Era in the coming time. Around 20 plus Abuse Deterrent Formulations of opioids are in the pipeline and most of them are ER formulations which use different AD tech platform to make its ADF. Amongst these pipeline ADF drugs, 6 are of Hydrocodone, 8 are of Morphine and 6 are of Oxycodone based ADF formulations. New NCEs targeting Opioids receptor are in pipeline which reduces Opioids abuse by its MoA (slow rate of entry in Brain) and may have potential to deal with reducing opioid abuse through restricting oral intake in coming years. US Opioids market is of $8b in size and of which extended release formulations contribute 50%. ADF ER formulations and its generic versions & New NCEs targeting Opioid receptor will drive the growth of opioid market in US and Europe in coming years. Late stage NCE pipeline drugs (Cebranopadol, Mirogabalin, NKT-181, AVP-923,) and Novel technologies targeting formulation change in old generic drugs (ORB-201, OX-51, ARX-04,CL-108, once daily Pregabalin..) for pain management has potential to reduce opioids use in future to treat pain. While TRKA receptor antagonist, NAV1.7 sodium channel modulator inhibitor and angiotension II antagonist are few new MoA which has promising drug in clinical development for moderate to severe pain management. Key Topics Covered: 1. Executive Summary 2. Management of Pain
3. FDA Schedule for controlled substances and advantage of Schedule III over II
4. FDA Perspective on Abuse deterrent formulations (Opioids) 5. Approved Abuse deterrent Formulations by FDA - Development , label claim, Technology and current prescription trend 6. Abuse Deterrent Technology Platforms employed in marketed drugs and pipeline 7. Pipeline analysis of Novel Technologies and new mechanisms in Pain management 8. Late stage pipeline developments in neuropathic pain Appendix - I FDA Guidelines for the development of abuse Deterrent Formulations Appendix- II General Principles for Evaluating the Abuse deterrent Generic Solid Oral Opioid Drug Products Companies Mentioned - AbbVie - AcelRx pharma - Acorda Therapeutics - Actavis - Acura Pharma - Acorda Therapeutics - Altus formulations - Alkermes - Algiax Pharmaceuticals - Amorsa Therapeutics - AnGes - AstraZeneca - Balerna - Biogen - BioDelivery Sciences International Inc - Biopharma - Cara Therapeutics - Catalent - Charleston - Celltech - Collegium Pharma - Convergence - Columbia Labs - Convatech - Daiichi Sankyo - Daewoong - Depomed - Durect - Egalet - Eli Lilly - Elite Pharma - Endo - Ensyce Bioscience - EpiCept - Flamel Technologies - Flexion Therapeutics - Forest - Glenmark - Grunenthal - GlaxoSmithKline - GW Pharma - Immune Pharmaceuticals - Impax Pharmaceuticals - Inspirion - Intelli Pharmaceutics - IRX Therapeutics - Johnson and Johnson - KemPharm - Kineta - Kunwha Pharmaceutical - Medallion Therapeutics - Mallinckrodt - Nektar - Novartis - Noven - Orbis Biosciences - Orexo - Otsuka - Pain Therapeutics - Pfizer - ProPharma - Purdue - Recro pharma - Relmada Therapeutics - Reckitt Benckiser pharmaceutical - Signature Therapeutics - Spinifex pharma - SPR Therapeutics - Strativa - Teikoku - Teva - Tesa Labtec GmpH - Trevena Inc - Tris Pharma - Valeant - ViroMed - Wooddiff Lake - Xenon Pharma - XenoPort For more information about this report visit http://www.researchandmarkets.com/research/qc...management Related Topics: Analgesics
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
